Whitehawk Therapeutics, Inc. - 8-K Filing

Whitehawk Therapeutics reports Q3 2026 net loss of $21.2 million and announces cash runway extending into 2H 2028. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $WHWK

Read the full article at SEC EDGAR

More Regulatory news